James A DeCaprio, M.D.
Professor of Medicine
Biography: Dr. DeCaprio received his MD in 1984 from the University at Buffalo School of Medicine and Biomedical Sciences. He completed his internal medicine residency at the University of Chicago, and his medical oncology fellowship at DFCI. In 1992, he joined the faculty of DFCI, where his laboratory has focused on mechanisms of cellular transformation and oncogenesis. He has authored several publications and is the recipient of many awards, such as: Scholar, Leukemia Society of America in 1997, American Society for Clinical Investigation in 1997, Biological and Biochemical Sciences HMS Award in Teaching in 2000, Stohlman Scholar of the Leukemia & Lymphoma Society in 2002, Harvard University GSAS Everett Mendelsohn Excellence in Mentoring Award in 2004, the Association of American Physicians in 2004 and the American Academy of Microbiology in 2016
Research and Expertise: A major area of interest of our laboratory is viral induced cancers. In particular, we study how oncogenic viral proteins enable the transformation of normal cells into cancer. We have found that expression of viral proteins has significant impact on the normal physiology of the cells including the cell cycle, signaling, and survival pathways. We are searching for additional mechanisms of viral induced transformation using a variety of approaches including identification of viral-host protein-protein interactions. We focus primarily on the small DNA tumor viruses especially SV40 and Merkel cell polyomavirus. We also study the contribution of Merkel cell polyomavirus to Merkel cell carcinoma, a highly aggressive and frequently lethal skin cancer. Another important interest of our laboratory is the mammalian cell cycle with a particular focus on the role of the retinoblastoma family of tumor suppressors. The retinoblastoma family includes pRb (RB1), p107 (RBL1) and p130 (RBL2). We recently identified the DREAM complex that contains DP1, Rb-related protein p130, E2F4 and the MuvB core complex of five proteins (LIN9, LIN37, LIN52 LIN54 and RBBP4). We have demonstrated that the DREAM complex serves as a master coordinator of cell cycle gene expression. We use mass-spectroscopy, expression profiling, chromatin immunoprecipitation and additional genomic approaches to understand how cell cycle dependent gene expression is regulated. We strive to combine these molecular insights with genomic analysis of human cancers to identify novel therapeutic opportunities.